Please assess the completion status of the following clinical trial:

Trial Title: A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Neuropathic Pain of the Foot and/or Lower Leg

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject is at least 18 years old~2. Subject is able and willing to comply with the follow-up schedule and protocol~3. Chronic, intractable pain in the foot and/or lower leg for at least 6 months~4. Failed conservative treatments for chronic pain including but not limited to pharmacological therapy, physical therapy and interventional pain procedures for chronic pain~5. Minimum baseline pain rating of 60 mm on the Visual Analog Scale in the primary region of pain~6. Subject is able to provide written informed consent~Exclusion Criteria:~1. Female subject of childbearing potential is pregnant/nursing, plans to become pregnant or is unwilling to use approved birth control~2. Escalating or changing pain condition within the past month as evidenced by investigator examination~3. Subject has had corticosteroid therapy at an intended site of stimulation within the past 30 days~4. Subject has had radiofrequency treatment of an intended target Dorsal Root Ganglion within the past 3 months~5. Subject currently has an active implantable device including implantable cardioverter defibrillator, pacemaker, spinal cord stimulator or intrathecal drug pump~6. Subject is unable to operate the device~7. Subjects with indwelling devices that may pose an increased risk of infection~8. Subjects currently has an active infection~9. Subject has participated in another clinical investigation within 30 days~10. Subject has a coagulation disorder or uses anticoagulants that, in the opinion of the investigator, precludes participation~11. Subject has been diagnosed with cancer in the past 2 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treated Subjects (Type: None): All subjects recruited and treated with the Axium neurostimulator

Based on this trial design, predict the completion outcome and termination type (if applicable).